Management ChangeAug 3, 2026, 08:16 AM
Royalty Pharma Appoints Greg Raskin as SVP, Head of Academic Initiatives
AI Summary
Royalty Pharma plc announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Raskin will lead the company's engagement with academic and non-profit institutions and manage the Royalty Pharma Translational Prize. CEO Pablo Legorreta highlighted Raskin's extensive experience in licensing, drug development, and investing as crucial for deepening the company's scientific community engagement and supporting innovation.
Key Highlights
- Royalty Pharma appointed Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives.
- Raskin's appointment is effective August 2026.
- He will lead outreach with academic and non-profit institutions and oversee the Translational Prize.
- Raskin previously served as Senior Vice President, Technology Development at Memorial Sloan Kettering Cancer Center.
- His background includes roles at AllianceBernstein, Baker Brothers Investments, and McKinsey & Company.
- Raskin holds an M.D. from Yale School of Medicine and a B.A. from Yale College.
Price Impact
More from RPRX